CRCatherine Rehm

Catherine Rehm

*This is an algorithmically generated author record based on publicly available information.

Catherine Rehm has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HIV-2 Infection with Elevated Immune Activation but No Detectable Viral RNA or DNA in Blood

    by Chuen-Yen Lau, Pia Gabrielle Gorme, Nina Sharma, Danielle Konlian, Robin Dewar, Perrine Lallemand, Jeroen Highbarger, Camilla Nusbaum, Jeffrey A. Johnson, Vickie Sullivan, et al.

    HIV-2 infection results in progressive CD4 lymphopenia and death if untreated. The course of HIV-2 infection is more indolent than HIV-1, and the viral and immune mechanisms responsible for this slower pathogenesis are incompletely understood. Persistent inflammation with elevations in cellular and soluble markers of immune activation is a characteristic feature of HIV-2 infection and has been reported to be related to levels of HIV-infected cells in peripheral blood. Here we report an individual with HIV-2 who had persistently elevated levels of activated CD8 lymphocyte subsets that were significantly higher than those quantified in a set of controls without HIV matched for age, sex, and race. Despite elevated levels of immune activation, no detectable HIV-2 RNA or proviral DNA was present in blood. Without undergoing antiretroviral therapy, longitudinal analysis revealed this sustained immune activation was not associated with a progressive CD4 lymphopenia or evidence of disease complications. The presence of strong immune responses without detectable levels of HIV-2 nucleic acid complicates diagnostic testing for HIV-2, and highlights gaps in our understanding of HIV-2 pathogenesis.

  • Open Access

    A Combination of M50I and V151I Polymorphic Mutations in HIV-1 Subtype B Integrase Results in Defects in Autoprocessing

    by Jun Yang, Ming Hao, Muhammad A. Khan, Muhammad T. Rehman, Helene C. Highbarger, Qian Chen, Suranjana Goswami, Brad T. Sherman, Catherine A. Rehm, Robin L. Dewar, et al.

    We have recently reported that a recombinant HIV-1NL4.3 containing Met-to-Ile change at codon 50 of integrase (IN) (IN:M50I) exhibits suppression of the virus release below 0.5% of WT HIV, and the released viral particles are replication-incompetent due to defects in Gag/GagPol processing by inhibition of the initiation of autoprocessing of GagPol polyproteins in the virions and leads to replication-incompetent viruses. The coexisting Ser-to-Asn change at codon 17 of IN or Asn-to-Ser mutation at codon 79 of RNaseH (RH) compensated the defective IN:M50I phenotype, suggesting that both IN and RH regulate an HIV infectability. In the current study, to elucidate a distribution of the three mutations during anti-retroviral therapy among patients, we performed a population analysis using 529 plasma virus RNA sequences obtained through the MiSeq. The result demonstrated that 14 plasma HIVs contained IN:M50I without the compensatory mutations. Comparing the sequences of the 14 viruses with that of the defective virus illustrated that only Val-to-Ile change at codon 151 of IN (IN:V151I) existed in the recombinant virus. This IN:V151I is known as a polymorphic mutation and was derived from HIVNL4.3 backbone. A back-mutation at 151 from Ile-to-Val in the defective virus recovered HIV replication capability, and Western Blotting assay displayed that the back-mutation restored Gag/GagPol processing in viral particles. These results demonstrate that a combination of IN:M50I and IN:V151I mutations, but not IN:M50I alone, produces a defective virus.


  • Open Access

    Dynamic Shifts in the HIV Proviral Landscape During Long Term Combination Antiretroviral Therapy: Implications for Persistence and Control of HIV Infections

    by Elizabeth M. Anderson, Francesco R. Simonetti, Robert J. Gorelick, Shawn Hill, Monica A. Gouzoulis, Jennifer Bell, Catherine Rehm, Liliana Pérez, Eli Boritz, Xiaolin Wu, et al.

    Combination antiretroviral therapy (cART) controls but does not eradicate HIV infection; HIV persistence is the principal obstacle to curing infections. The proportion of defective proviruses increases during cART, but the dynamics of this process are not well understood, and a quantitative analysis of how the proviral landscape is reshaped after cART is initiated is critical to understanding how HIV persists. Here, we studied longitudinal samples from HIV infected individuals undergoing long term cART using multiplexed Droplet Digital PCR (ddPCR) approaches to quantify the proportion of deleted proviruses in lymphocytes. In most individuals undergoing cART, HIV proviruses that contain gag are lost more quickly than those that lack gag. Increases in the fraction of gag-deleted proviruses occurred only after 1–2 years of therapy, suggesting that the immune system, and/or toxicity of viral re-activation helps to gradually shape the proviral landscape. After 10–15 years on therapy, there were as many as 3.5–5 times more proviruses in which gag was deleted or highly defective than those containing intact gag. We developed a provirus-specific ddPCR approach to quantify individual clones. Investigation of a clone of cells containing a deleted HIV provirus integrated in the HORMAD2 gene revealed that the cells underwent a massive expansion shortly after cART was initiated until the clone, which was primarily in effector memory cells, dominated the population of proviruses for over 6 years. The expansion of this HIV-infected clone had substantial effects on the overall proviral population.


  • Open Access

    No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication

    by G. Bozzi, F. R. Simonetti, S. A. Watters, E. M. Anderson, M. Gouzoulis, M. F. Kearney, P. Rote, C. Lange, W. Shao, R. Gorelick, et al.

    Long-term persistence, not ongoing virus replication, is primarily responsible for maintaining HIV during antiretroviral therapy.


  • Virion incorporation of integrin α4β7 facilitates HIV-1 infection and intestinal homing

    by Christina Guzzo, David Ichikawa, Chung Park, Damilola Phillips, Qingbo Liu, Peng Zhang, Alice Kwon, Huiyi Miao, Jacky Lu, Catherine Rehm, et al.

    The intestinal mucosa is a key anatomical site for HIV-1 replication and CD4+ T cell depletion. Accordingly, in vivo treatment with an antibody to the gut-homing integrin α4β7 was shown to reduce viral transmission, delay disease progression, and induce persistent virus control in macaques challenged with simian immunodeficiency virus (SIV). We show that integrin α4β7 is efficiently incorporated into the envelope of HIV-1 virions. Incorporated α4β7 is functionally active as it binds mucosal addressin cell adhesion molecule–1 (MAdCAM-1), promoting HIV-1 capture by and infection of MAdCAM-expressing cells, which in turn mediate trans-infection of bystander cells. Functional α4β7 is present in circulating virions from HIV-infected patients and SIV-infected macaques, with peak levels during the early stages of infection. In vivo homing experiments documented selective and specific uptake of α4β7+ HIV-1 virions by high endothelial venules in the intestinal mucosa. These results extend the paradigm of tissue homing to a retrovirus and are relevant for the pathogenesis, treatment, and prevention of HIV-1 infection.


  • Open Access

    1 Analysis of intra-patient, full length HIV gagsequences identifies regions of variability

    by E. Anderson, M. Gouzoulis, A. Ganesan, C. Rehm, S. Jones, F. Maldarelli